Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.
复制标题
DOI：
10.1080/13543784.2022.2086120
复制
发表时间：
2022-08
影响因子：
6.1
通讯作者：
Krause, Robert
中科院分区：
文献类型：
--
作者：
Hoenigl, Martin;Sprute, Rosanne;Arastehfar, Amir;Perfect, John R.;Lass-Floerl, Cornelia;Bellmann, Romuald;Prattes, Juergen;Thompson, George R., III;Wiederhold, Nathan P.;Al Obaidi, Mohanad M.;Willinger, Birgit;Arendrup, Maiken C.;Koehler, Philipp;Oliverio, Matteo;Egger, Matthias;Schwartz, Ilan S.;Cornely, Oliver A.;Pappas, Peter G.;Krause, Robert
关键词：
侵袭性念珠菌感染的流行病学正在不断发展。由非白色念珠菌引起的感染。正在增加；然而，抗真菌药物管道比以往任何时候都更有前途，并且富含具有新作用机制的重新用途药物和制剂。尽管取得了进展，但治疗侵袭性念珠菌病的需求仍然未得到满足，并且可口服或具有中枢神经系统渗透性的抗真菌药物仍然太少。作者阐明了那些处于临床开发后期的对念珠菌具有活性的抗真菌药物。讨论了作用机制以及关键的药代动力学和药效学特性。对研究药物 MAT-2203、奥替康唑、ATI-2307、VL-2397、NP-339 和重新利用的药物米替福辛的未来潜在作用提供了见解。 Ibrexafungerp 和 fosmanogepix 具有新颖的作用机制，将为治疗念珠菌感染（包括由多重耐药念珠菌引起的感染）提供有效的选择。 Rezafungin 是一种半衰期较长的棘白菌素，可以每周给药一次，对于门诊治疗和预防特别有价值。尽管如此，仍然迫切需要收集研究药物的临床数据，特别是在当前唑类耐药和多重耐药念珠菌不断增加的情况下，
The epidemiology of invasive Candida infections is evolving. Infections caused by non-albicans Candida spp. are increasing; however, the antifungal pipeline is more promising than ever and is enriched with repurposed drugs and agents that have new mechanisms of action. Despite progress, unmet needs in the treatment of invasive candidiasis remain and there are still too few antifungals that can be administered orally or that have CNS penetration. The authors shed light on those antifungal agents active against Candida that are in late-stage clinical development. Mechanisms of action and key pharmacokinetic and pharmacodynamic properties are discussed. Insights are offered on the potential future roles of the investigational agents MAT-2203, oteseconazole, ATI-2307, VL-2397, NP-339, and the repurposed drug miltefosine. Ibrexafungerp and fosmanogepix have novel mechanisms of action and will provide effective options for the treatment of Candida infections (including those caused by multiresistant Candida spp). Rezafungin, an echinocandin with an extended half-life allowing for once weekly administration, will be particularly valuable for outpatient treatment and prophylaxis. Despite this, there is an urgent need to garner clinical data on investigational drugs, especially in the current rise of azole-resistant and multi-drug resistant Candida spp,
登录
查看更多内容
影响因子：
4.9
作者：
Duncan V;Smith D;Simpson L;Lovie E;Katvars L;Berge L;Robertson J;Smith S;Munro C;Mercer D;O'Neil D
通讯作者：
O'Neil D
影响因子：
4.9
作者：
Angeles Bordallo-Cardona, Maria;Agnelli, Caroline;Guinea, Jesus
通讯作者：
Guinea, Jesus
DOI：
10.1016/j.ijantimicag.2020.106049
发表时间：
2020-08-01
影响因子：
10.8
作者：
Barreto, Thayna Lopes;Rossato, Luana;Ishida, Kelly
通讯作者：
Ishida, Kelly
影响因子：
4.9
作者：
Bowman, JC;Hicks, PS;Douglas, CM
通讯作者：
Douglas, CM
影响因子：
14.2
作者：
Arendrup, M. C.;Meletiadis, J.;Guinea, J.
通讯作者：
Guinea, J.